Bioactivity of turmeric-derived curcuminoids and related metabolites in breast cancer

Current Pharmaceutical Design

Volumn 19, Issue 34, 2013, Pages 6218-6225

  Wright, Laura E ^a   Frye, Jen B ^a   Gorti, Bhavana ^a   Timmermann, Barbara N ^b   Funk, Janet L ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

Breast; Cancer; Curcumin; Curcuminoid; Ferulic acid; Ginger; PTHrP; Tetrahydrocurcuminoids

Indexed keywords

(10) GINGEROL; (6) GINGEROL; (8) GINGEROL; ANTINEOPLASTIC AGENT; CURCUMIN; CURCUMINOID DERIVATIVE; DEMETHOXYCURCUMIN; DIDEMETHOXYCURCUMIN; ESSENTIAL OIL; FERULIC ACID; GINGEROL; PARATHYROID HORMONE RELATED PROTEIN; PLANT MEDICINAL PRODUCT; TETRAHYDROCURCUMINOID; TURMERIC; UNCLASSIFIED DRUG; VANILLIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; DRUG EFFECT; DRUG METABOLISM; HUMAN; HUMAN CELL; IC 50; METABOLITE; OSTEOLYSIS; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN SECRETION; TUMOR CELL;

ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL SURVIVAL; CURCUMA; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GINGER; HUMANS; PARATHYROID HORMONE-RELATED PROTEIN; PLANT EXTRACTS; RHIZOME;

EID: 84887978737     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319340013     Document Type: Article

References (47)

1. Centers for Disease Control and Prevention [homepage on the internet]. Atlanta GA: 1999-2008 Incidence and Mortality Web-Based Report. Department of Health and Human Services, Center for Disease Control and Prevention, and National Cancer Institute. Available from: http://www. cdc. gov/uscs. [Accessed 26 Oct 2012].
2. World Health Organization, International Agency for Research on Cancer [homepage on the internet] Lyon, France: GLOBOCAN 2008. Available from: http://globocan. iarc. fr. [Accessed 26 Oct 2012].
3. Ji JL, Huang XF, Zhu HL. Curcumin and its formulations: potential anti-cancer agents. Anticancer Agents Med Chem 2012; 12: 210-8.
4. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 8: 584-93.
5. Wright LE, Frye JB, Lukefahr AL et al. Curcuminoids block TGF-α signaling in human breast cancer cells and limit osteolysis in a murine model of breast cancer bone metastasis. J Nat Prod 2012 (in press).
6. Krishnaswamy K. Traditional Indian spices and their health significance. Asia Pac J Clin Nutr 2008; 17 Suppl 1: 265-8.
7. Funk JL, JB Frye, JN Oyarzo, et al. Efficacy and mechanism of action of turmeric supplements in the treatment of experimental arthritis. Arth Rheum 2006; 54: 3452-64.
8. Sharma RA, Steward WP, Gescher AJ. Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol 2007; 4: 453-70.
9. Liang S, Ji HF. The pharmacology of curcumin: is it the degradation products? Trends Mol Med 2012; 18: 138-43.
10. Funk JL, Frye JB, Oyarzo JN, Zhang H, Timmermann BN. Antiarthritic effects and toxicity of the essential oils of turmeric (Curcuma longa L.). J Agric Food Chem 2010; 58: 842-9.
11. Benny M, Antony B. Bioavailability of Biocurcumax (BCM-095™). Spice India 2006; 19: 1-51.
12. Subik K, Lee JF, Baxter L et al. The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (Auckl) 2010; 20: 35-41.
13. Rodler E, Korde L, Gralow J. Current treatment options in triple negative breast cancer. Breast Dis 2010; 32: 99-122.
14. Funk JL, Frye JB, Oyarzo JN, Timmermann BN. Comparative effects of two gingerol-containing Zingiber officinale extracts on experimental rheumatoid arthritis. J Nat Prod 2009; 72: 403-7.
15. Funk JL, Frye JB, Oyarzo JN, Zhang H, Timmermann BN. Antiarthritic effects and toxicity of the essential oils of turmeric (Curcuma longa L.). J Agric Food Chem 2010; 58: 842-9.
16. Funk JL, Oyarzo JN, Frye JB et al. Turmeric extracts containing curcuminoids prevent experimental rheumatoid arthritis. J Nat Prod 2006; 69: 351-5.
17. Pan MH, Huang TM, Lin JK. Biotransformation of curcumin through reduction and glucoronidation in mice. Drug Metabolism Disposition 1999; 27: 486-94.
18. Wang YJ, Pan MH, Cheng AL et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 1997; 15: 1867-76.
19. Pfeiffer E, Hohle S, Solyom AM, Metzler M. Studies on the stability of turmeric constituents. J Food Eng 2003; 56: 257-59.
20. Dempe JS, Pfeiffer E, Grimm AS, Metzler M. Metabolism of curcumin and induction of mitotic catastrophe in human cancer cells. Mol Nutr Food Res 2008; 52: 1074-81.
21. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm 2007; 4: 807-18.
22. Holder GM, Plummer JL, Ryan AJ. The metabolism and excretion of curcumin (1, 7-bis-(4-hydroxy-3-methoxyphenyl)-1, 6-heptadiene-3, 5-dione) in the rat. Xenobiotica 1978; 12: 761-8.
23. Gupta SC, Prasad S, Kim JH et al. Multitargeting by curcumin revealed by molecular interaction studies. Nat Prod Rep 2011; 28: 1937-55.
24. Woo JH, Kim YH, Choi YJ et al. Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis 2003; 24: 1199-208.
25. Liu Q, Loo WT, Sze SC, Tong Y. Curcumin inhibits cell proliferation of MDA-MB-231 and BT-483 breast cancer cells mediated by down-regulation of NFkappaB, cyclinD and MMP-1 transcription. Phytomedicine 2009; 16: 916-22.
26. Sun SH, Huang HC, Huang C, Lin JK. Cycle arrest and apoptosis in MDA-MB-231/Her2 cells induced by curcumin. Eur J Pharmacol 2012; 690: 22-30.
27. Basile V, Ferrari E, Lazzari S, Belluti S, Pignedoll F, Imbriano C. Curcumin derivatives: molecular basis of their anti-cancer activity. Biochem Pharmacol 2009; 15: 1305-15.
28. Han G, Cui JJ, Bi R, Zhao LL, Zhang WG. [Study on stability of curcumine, demethoxycurcumin and bisdemethoxycurcumin]. Zhongguo Zhong Yao Za Zhi 2008; 33: 2611-4.
29. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massague J, Mundy GR, Guise TA. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999; 103: 197-206.
30. Boonrao M, Yodkeeree S, Ampasavate C, Anuchapreeda S, Limtrakul P. The inhibitory effect of turmeric curcuminoids on matrix metalloproteinase-3 secretion in human invasive breast carcinoma cells. Arch Pharm Res 2010; 33: 989-98.
31. Jeong GS, Oh GS, Pae HO et al. Comparative effects of curcuminoids on endothelial heme oxygenase-1 expression: ortho-methoxy groups are essential to enhance heme oxygenase activity and protection. Exp Mol Med 2006; 38: 393-400.
32. Suzuki M, Nakamura T, Iyoki S et al. Elucidation of the antiallergic activities of curcumin-related compounds with a special reference to their anti-oxidative activities. Biol Pharm Bull 2005; 8: 1438-43.
33. Fujisawa S, Ishihara M, Murakami Y, Atsumi T, Kadoma Y, Yokoe I. Predicting the biological activities of 2-methoxyphenol antioxidants: effects of dimers. In vivo 2007; 2: 181-8.
34. Thapliyal R, Maru GB. Inhibition of cytochrome P450 isozymes by curcumins in vitro and in vivo. Food Chem Toxicol 2001; 39: 541-7.
35. Yodkeeree S, Chaiwangyen W, Garbisa S, Limtrakul P. Curcumin, demethoxycurcumin and bisdemethoxycurcumin differentially inhibit cancer cell invasion through the down-regulation of MMPs and uPA. J Nutr Biochem 2007; 20: 87-95.
36. Metzler M, Pfeiffer E, Schulz SI, Dempe JS. Curcumin uptake and metabolism. Biofactors. 2012 Sep 20. doi: 10. 1002/biof. 1042. [Epub ahead of print].
37. Dhillon N, Sung B, Kurzrock R, Aggarwal BB. Could antitumor activity of curcumin in patients be due to its metabolites? A response. Clin Cancer Res 2009; 15: 7108-9.
38. Murakami Y, Hirata A, Ito S et al. Re-evaluation of cyclooxygenase-2-inhibiting activity of vanillin and guaiacol in macrophages stimulated with lipopolysaccharide. Anticancer Res 2007; 27: 801-7.
39. Jung KJ, Go EK, Kim JY, Yu BP, Chung HY. Suppression of agerelated renal changes in NF-αB and its target gene expression by dietary ferulate. J Nutr Biochem 2009; 20: 378-88.
40. Jayaprakasam B, Vanisree M, Zhang Y, Dewitt DL, Nair MG. Impact of alkyl esters of caffeic and ferulic acids on tumor cell proliferation, cyclooxygenase enzyme, and lipid peroxidation. J Agric Food Chem 2006; 54: 5375-81.
41. Griesser M, Pistis V, Suzuki T, Tejera N, Pratt DA, Schneider C. Autoxidative and cyclooxygenase-2 catalyzed transformation of the dietary chemopreventative agent curcumin. J Bio Chem 2011; 286: 1114-24.
42. Gordon ON, Schneider C. Vanillin and ferulic acid: not the major degradation products of curcumin. Trends Mol Med 2012; 18: 361-3.
43. Barone E, Calabrese V, Mancuso C. Ferulic acid and its therapeutic potential as a hormetin for age-related diseases. Biogerontology 2009; 10: 97-108.
44. Klepacka J, Fornal L. Ferulic acid and its position among the phenolic compounds of wheat. Crit Rev Food Sci Nutr 2006; 46: 639-47.
45. Yoysungnoen P, Wirachwong P, Changtam C, Suksamrarn A, Patumraj S. Anti-cancer and anti-angiogenic effects of curcumin and tetrahydrocurcumin on implanted hepatocellular carcinomas in nude mice. World J Gastroenterol 2008; 14: 2003-9.
46. Lin JK. Suppression of protein kinase C and nuclear oncogene expression as possible action mechanisms of cancer chemoprevention by Curcumin. Arch Pharm Res 2004; 27: 683-92.
47. Wu JC, Lai CS, Badmaev V, Nagabhushanam K, Ho CT, Pan MH. Tetrahydrocurcumin, a major metabolite of curcumin, induced autophagic cell death through coordinative modulation of PI3K/Akt-mTOR and MAPK signaling pathways in human leukemia HL-60 cells. Mol Nutr Food Res 2011; 55: 1646-54.